



## Interface Prescribing & New Therapies Subgroup



January 2013

### **Fluocinolone (Iluvien®) for Diabetic Macular Oedema (DMO)**

The Interface Prescribing and New Therapies Subgroup discussed the above drug at its meeting on the 28<sup>th</sup> January 2013. The recommendation of this subgroup is as follows:\*

The Interface Prescribing & New Therapies Subgroup of the GMMM considered the use of fluocinolone for diabetic macular oedema.

**The group recommends the use of fluocinolone acetonide for diabetic macular oedema (DMO) as per NICE TA271.**

According to set criteria fluocinolone was deemed to be low priority for funding.

Review date: January 2015

\* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm their risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.

SUPERSEDED BY NICE GUIDANCE